Business Context and Reporting Period
Company: iSpecimen Inc. (ISPC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2025
Business Overview: iSpecimen operates a proprietary online marketplace connecting medical researchers with hospitals and laboratories to procure human biospecimens (blood, tissue, cells) and associated data. The company operates as a single reporting segment with headquarters in Woburn, Massachusetts.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $1,057,510 | $2,289,993 |
| Net Loss | $(1,658,396) | $(2,902,117) |
| Loss Per Share (Basic & Diluted) | $(0.71) | $(6.36) |
| Cash and Cash Equivalents | $782,563 | $2,089,891 |
| Working Capital | $(3,391,716) | $(2,182,488) |
| Total Assets | $6,843,256 | $9,350,230 |
| Total Liabilities | $5,174,743 | $6,039,222 |
| Net Cash Used in Operating Activities | $(1,095,845) | $(2,072,363) |
Note: Financial data reflects the retroactive effect of a 1-for-20 reverse stock split effective September 13, 2024.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 54% to $1.06 million. This was primarily driven by a 56% decrease in specimen count (2,309 vs. 5,241), largely due to a change in revenue recognition policy in Q4 2024 (shifting from recognizing revenue upon accession to recognizing upon delivery). The average selling price per specimen increased 5% to $458.
- Expense Reduction: Total operating expenses decreased 49% to $2.70 million. Significant reductions were seen in General and Administrative expenses (down 64%) and Technology expenses (down 40%) due to workforce reductions and decreased capitalization of software development costs.
- Improved Net Loss: Net loss narrowed 43% to $1.66 million, driven by the substantial reduction in operating expenses.
- Liquidity Position: Cash and cash equivalents decreased by $1.10 million (58%) to $782,563. The company reported a negative working capital of $3.39 million.
Outlook, Risks, and Contingencies
Going Concern Uncertainty
Management has raised substantial doubt regarding the company's ability to continue as a going concern for one year from the filing date. The company has an accumulated deficit of $73.5 million and relies on raising additional capital or achieving profitable operations to sustain liquidity.
Legal Proceedings
- Focus Technology Solutions: A dispute regarding non-payment for IT services resulted in the temporary shutdown of the iSpecimen Marketplace (Jan 25 - Feb 12, 2025). A settlement of $500,000 was agreed upon, but the vendor failed to fully restore the platform. The company withheld further payments and is asserting counterclaims. The court ordered the company to deposit 15% of revenue into a dedicated account up to $420,000 as pre-judgment security.
- Former CIO Arbitration: A demand for arbitration filed by the former Chief Information Officer regarding bonus and severance payments was settled for $215,000 in January 2025.
Sales Tax Liability
The company identified a historical sales tax liability. As of March 31, 2025, the accrued liability for sales tax was approximately $378,000, with related interest and penalties of approximately $104,000. The company is actively collecting these amounts from non-exempt customers.
Management Commentary
Management is executing a cost-reduction strategy, having reduced monthly compensation costs by approximately 93% and technology costs by 73% compared to Q1 2024. The company is shifting focus to high-value suppliers and implementing an account-based sales approach.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $782,563 cash balance against the negative working capital of $3.39 million and ongoing burn rate.
- Revenue Recognition Policy: Confirm the impact of the Q4 2024 change from "accession" to "delivery" basis on future revenue comparability.
- Legal Exposure: Monitor the status of the Focus Technology Solutions litigation, specifically the enforcement of the $420,000 pre-judgment security deposit and the outcome of counterclaims.
- Sales Tax Resolution: Track the recovery of the $378,000 sales tax liability from customers and the status of Voluntary Disclosure Agreements (VDAs).
- Capital Raising: Assess the company's ability to secure additional funding given the "substantial doubt" disclosure and recent debt repayment history.